Department of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinju-ku, Tokyo 160-8582, Japan.
Neurosci Res. 2010 Apr;66(4):345-52. doi: 10.1016/j.neures.2009.12.008. Epub 2009 Dec 21.
Hearing impairment can be the cause of serious socio-economic disadvantages. Recent studies have shown inflammatory responses in the inner ear co-occur with various damaging conditions including noise-induced hearing loss. We reported pro-inflammatory cytokine interleukin-6 (IL-6) was induced in the cochlea 6h after noise exposure, but the pathophysiological implications of this are still obscure. To address this issue, we investigated the effects of IL-6 inhibition using the anti-IL-6 receptor antibody (MR16-1). Noise-exposed mice were treated with MR16-1 and evaluated. Improved hearing at 4kHz as measured by auditory brainstem response (ABR) was noted in noise-exposed mice treated with MR16-1. Histological analysis revealed the decrease in spiral ganglion neurons was ameliorated in the MR16-1-treated group, while no significant change was observed in the organ of Corti. Immunohistochemistry for Iba1 and CD45 demonstrated a remarkable reduction of activated cochlear macrophages in spiral ganglions compared to the control group when treated with MR16-1. Thus, MR16-1 had protective effects both functionally and pathologically for the noise-damaged cochlea primarily due to suppression of neuronal loss and presumably through alleviation of inflammatory responses. Anti-inflammatory cytokine therapy including IL-6 blockade would be a feasible novel therapeutic strategy for acute sensory neural hearing loss.
听力损伤可能导致严重的社会经济劣势。最近的研究表明,内耳的炎症反应与各种损伤情况同时发生,包括噪声性听力损失。我们报告说,在噪声暴露后 6 小时,耳蜗中就会诱导产生促炎细胞因子白细胞介素-6 (IL-6),但这一现象的病理生理意义仍不清楚。为了解决这个问题,我们使用抗 IL-6 受体抗体 (MR16-1) 研究了 IL-6 抑制的效果。用 MR16-1 处理噪声暴露的小鼠并进行评估。用听觉脑干反应 (ABR) 测量,噪声暴露的小鼠在接受 MR16-1 治疗后,4kHz 时的听力得到改善。组织学分析显示,MR16-1 治疗组的螺旋神经节神经元数量减少得到改善,而耳蜗毛细胞没有明显变化。用 MR16-1 处理后,免疫组织化学染色显示螺旋神经节中的活化耳蜗巨噬细胞数量明显减少。因此,MR16-1 对噪声损伤的耳蜗具有功能和病理上的保护作用,主要是由于神经元损失的抑制,可能是通过减轻炎症反应。包括 IL-6 阻断在内的抗炎细胞因子治疗可能是急性感觉神经性听力损失的一种可行的新治疗策略。